Cui, Xiao-Long http://orcid.org/0000-0002-1345-2271
Nie, Ji
Ku, Jeremy
Dougherty, Urszula
West-Szymanski, Diana C.
Collin, Francois
Ellison, Christopher K.
Sieh, Laura http://orcid.org/0000-0003-3238-016X
Ning, Yuhong
Deng, Zifeng
Zhao, Carolyn W. T.
Bergamaschi, Anna
Pekow, Joel
Wei, Jiangbo http://orcid.org/0000-0003-2691-6490
Beadell, Alana V.
Zhang, Zhou http://orcid.org/0000-0002-9639-052X
Sharma, Geeta http://orcid.org/0000-0003-4144-2799
Talwar, Raman
Arensdorf, Patrick
Karpus, Jason
Goel, Ajay http://orcid.org/0000-0003-1396-6341
Bissonnette, Marc
Zhang, Wei http://orcid.org/0000-0003-0875-263X
Levy, Samuel http://orcid.org/0000-0002-4444-5103
He, Chuan http://orcid.org/0000-0003-4319-7424
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (HG006827, R01CA223662, U01CA217078)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 12 August 2020
Accepted: 3 November 2020
First Online: 2 December 2020
Competing interests
: C.H. is a scientific founder and scientific advisory board member of Accent Therapeutics, Inc. C.H. and W.Z. are shareholders of Epican Genetech, Ltd. S.L. is the Chief Executive Officer and Chief Scientific Officer of Bluestar Genomics, Inc. C.K.E., Y.N., A.Bergamaschi, and S.L. are employees of Bluestar Genomics and along with J.Ku., F.C., R.T., and P.A. are shareholders of the company. Other authors declare no competing interests.